ATRC

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Atricure Inc

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator ® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.
CEO
Employees
750
Headquarters

News

AtriCure Inc (ATRC) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
Jul 31, 2024 15:00pm

AtriCure Inc (ATRC) Q2 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Positive Cash Flow Amid Increased Expenses


Source:GuruFocus
Q2 2024 AtriCure Inc Earnings Call Transcript
Jul 31, 2024 13:20pm

Q2 2024 AtriCure Inc Earnings Call Transcript


Source:GuruFocus
AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript
Jul 31, 2024 04:01am

No summary available.


Source:Seeking Alpha
ATRC Stock Earnings: AtriCure Meets EPS, Beats Revenue for Q2 2024
Jul 31, 2024 01:55am

AtriCure (NASDAQ: ATRC ) just reported results for the second quarter of 2024. AtriCure reported earnings per share of -17 cents. This met the analyst estimate for EPS of -17 cents. The company reported revenue of $116.27 million. This was 0.08% better than the analyst estimate for revenue of $116.18 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace Legendary Investor Predicts: “Forget AI… THIS Technology Is the Future” The post ATRC Stock Earnings: AtriCure Meets EPS, Beats Revenue for Q2 2024 appeared first on InvestorPlace .


Source:InvestorPlace
AtriCure Non-GAAP EPS of -$0.17 in-line, revenue of $116.3M beats by $0.12M
Jul 30, 2024 21:12pm

AtriCure (ATRC) reports Q2 earnings in-line with non-GAAP EPS of -$0.17, revenue beats expectations at $116.3M (+15.3% Y/Y).


Source:Seeking Alpha
AtriCure Reports Second Quarter 2024 Financial Results
Jul 30, 2024 20:01pm

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2024 financial results. “Our second quarter results reflect strong growth worldwide, underscored by our pain management and open AtriClip franchises, as we continued to Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference | ATRC Stock News
Jul 29, 2024 12:00pm

AtriCure to present at Canaccord Genuity''s Global Growth Conference. Learn about their innovations in atrial fibrillation treatments and growth strategies. Live webcast available August 13, 2024, at 10:30 am EST.


Source:Stock Titan
AtriCure''s Latest Projects And European Market Entry, Advancing Cardiac Care
Jul 25, 2024 12:51pm

No summary available.


Source:Seeking Alpha
AtriCure receives regulatory approval to sell AtriClip devices in China
Jul 23, 2024 13:47pm

AtriCure receives regulatory approval to sell AtriClip devices in China, based on clinical data showing safety and efficacy.


Source:Seeking Alpha
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
Jun 28, 2024 10:50am

Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake. In this case, I’ve chosen the arbitrary price level of $20. All of the shares discussed in this article are priced between $20 and $25. Each share is also projected to double in price over the next 12 to 18 months. Make no mistake about it, this is risky investing. However, at this price range we aren’t talking about penny stocks , so we have at least graduated above that level of risk. Make your own individual determination as it relates to the amount of risk you are willing to assume. As for industries, there’s a reasonably diverse offering of companies represented here. As expected, there are a few biotechnology firms that are well represented at the penny stock level. Let’s take a look at these companies to buy for growth and their stocks. AtriCure (ATRC) Source: Dmytro Zinkevych / Shutterstock.com AtriCure (NASDAQ: ATRC ) is a stock representing a manufacturer and seller of devices used in the surgical ablation of cardiac tissue and other ablation procedures.


Source:InvestorPlace